Korean pharmaceutical company Chong Kun Dang, has received approval from the Ministry of Health of Ukraine to conduct Phase III clinical trials of Nafabeltan, intended to treat COVID-19, in the country
It is reported that clinical trials of the drug in Ukraine will take place in accordance with the plan approved by the Korean Ministry of Food and Drug Safety in April.
Nafabeltan is known as a medicine for acute pancreatitis. The company plans to conduct phase III clinical trials of the drug in eight countries, including Brazil, India, Thailand, Russia, Argentina and Peru.
Chong Kun Dang plans to evaluate the efficacy and safety of Nafabeltan using double-blind tests and other testing methods in 600 patients with severe COVID-19.U.S. demands to take revenge on Russia because of the “Havana syndrome” from the Americans